Pierre-Emmanuel RAUTOU M.D., Ph.D.

Course and current status

EDUCATION AND TRAINING
* 2015: Research direction accreditation (Habilitation de direction de recherches”)
* 2011-2012: Postdoctoral research fellow, Hematology department, UNC Chapel Hill, NC, USA
* 2011: PhD. in vascular biology, summa cum laude, University of Paris 7, Paris, France
* 2008: Doctor of Medicine (MD), summa cum laude, University of Paris 7. Hepatology
* 2007: M.Sc. University of Paris and Inserm UMR-689 (France) 
* 2003-2006 and 2009: Medical Residency, Paris, France
* 1998-2003: Medical studies in University of Bordeaux, France
 
PROFESSIONAL EXPERIENCE   
* 2019–present: Inserm team leader, Inserm UMR-1149, Research center on Inflammation, Paris
* 2016–present: Full Professor, Hepatology Department, Beaujon Hospital, and University Paris Diderot, Paris-Clichy, France
* 2012–present: Head of the Splanchnic Hemodynamic Laboratory, Hepatology Department, Beaujon Hospital, Clichy, France
* 2012–2018: Project leader, Team “Endothelium pathophysiology”, Inserm UMR-970, Paris
* 2012–2016: Assistant Professor, Hepatology Department, Beaujon Hospital, and University Paris Diderot, Paris-Clichy, France
* 2009-present: Member of the Splanchnic Hemodynamic Laboratory, Hepatology Department, Beaujon Hospital, Clichy, France
* 2005-present: Night call in liver intensive care unit, Beaujon Hospital, Clichy, France

AWARD AND PRICES 
2018: European Association for the Study of the Liver (EASL) YI Award 
* 2017Paris region innovation award  
* 2014: United European Gastroenterology Rising Stars Award
* 2012: Paris Universities best thesis award winner (top 1% PhD in Paris and Paris region)
* 2012: New French Society of Atherosclerosis best thesis award winner
* 2009: Paris residents in medicine silver medal winner
* 2009: American Association for the study of the Liver  “Young Investigator Travel Award” 

CURRENT FUNDING   
French Research agency grant (ANR 2019-23), ECLIPSE, “TimE frame ControL of Inflammation by canonical and non-canonical autophagy to Prevent fatty liver diSease progrEssion"  (coordinator)
* French multicentric phase III clinical trial comparing apixaban vs. pacebo in patients with intrahepatic non cirrhotic portal hypertension (PHRC national), APIS; 2018-2022; (Coordinating Investigator)  
* French multicentric observational study testing microvesicles and interferon score to predict outcome of patients with cirrhosis (PHRC interregional), PROMICE; 2019-2022 (scientific coordinator) 
* RHU QUID-NASH, “quantitative imaging for NASH”, 2017-2022 (partner)
* French Research agency grant (ANR franco-german 2015-18), JAK-POT “Role of the JAK2V617F mutation in the pathophysiology of thrombosis in myeloproliferative diseases” (partner)

EDITORSHIP  
* 2018-present: Editorial board of J Hep Reports 
* 2017- present: Editorial board of Hepatology
* 2015-present: Editorial board of Clinical Science
* 2014-present: Editorial board of Journal of Hepatology 

SUPERVISON
* Currently: 2 PhD students, 2 Master 2 students
* Past: 1 PhD, 2 Pharmacy theses, 2 MD theses, 14 Master 2 students and 13 Master 1 students

-        Paris Universities best thesis award winner (2012);

-        New French Society of Atherosclerosis best thesis award winner (2012);

-        Paris residents in medicine silver medal winner (2009);

-        American Heart Association (AHA) post-doctoral fellowship (2012); 

Scientific summary

Overall, my research is focused on the role of vessels in liver diseases. On the clinical side, I am interested in primary vascular liver diseases (Budd-Chiari syndrome, extrahepatic portal vein thrombosis and obstruction of intrahepatic portal veins), as well as in vascular involvement in cirrhosis development and complications. On the basic side, my objectives are to identify the role of extracellular vesicles and of autophagy in liver diseases. 

Image d’exemple